15 Despite the relatively early stage of obesity pharmaceutical research in Arab countries, there is an increasing focus on this area
QC report including TIC RSD across QC injections Processed feature matrix: aligned peak list with retention time, m/z, adduct assignment, and per-sample intensity values Differential feature results: volcano plot (fold change vs FDR), feature lists stratified by annotation confidence level (MS1 only / MS1+MS2 / MS1+MS2+RT) Annotated metabolite table: HMDB accession, metabolite name, chemical class, pathway class, biosample annotation confidence KEGG pathway enrichment map: ranked pathways by impact score and FDR, colour-coded by direction of perturbation (enriched up vs down) Multivariate analysis plots: PCA scores plot (all samples), OPLS-DA S-plot and permutation test for compound MoA separation experiments MoA interpretation report: written mechanistic summary translating pathway findings into drug mechanism hypotheses, with off-target and toxicity pathway flags Compound comparison matrix (Mode 2): inter-compound metabolic fingerprint similarity scores and mechanism-class cluster dendrogram Representative Results Volcano plot: metabolome-wide drug response features Full-feature volcano plot from RP-LC-HRMS untargeted metabolomics, comparing compound-treated versus DMSO-vehicle control cells (n = 6 per group)
Standard escalation follows: 0.25mg weeks 1-4, 0.5mg weeks 5-8, 1.0mg weeks 9-12, with potential further increases to 1.7mg or 2.4mg based on response
Why So Many People Stop GLP-1 Drugs The findings are especially relevant because many people dont stay on GLP-1s long-term
GLP-1 drugs (injections) cost 8,000-10,000 depending on the dose
